Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoschisin (RS1) is a soluble, cell-surface lectin crucial for retinal structure and function. Encoded by the RS1 gene on chromosome Xp22.13, it is specifically expressed in photoreceptor and bipolar cells of the retina, as well as pinealocytes. The protein contains a discoidin domain and forms oligomeric structures (homo16mer) that facilitate strong membrane adhesion between retinal cells. RS1 acts as an extracellular cell adhesion molecule, binding to plasma membranes of photoreceptors and bipolar cells and interacts with Na/K ATPase complexes (α3/β2 isoforms). Mutations in RS1 cause X-linked juvenile retinoschisis, leading to retinal splitting and progressive vision loss. Key interacting partners include Na/K ATPase and SARM1, which are important for maintaining retinal tissue integrity and regulating intracellular signaling.
Currently, no drugs directly target RS1. Gene therapy approaches are under investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoschisin Protein (RS1).